Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2401 participants.
Also called NCT04363697
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 2,401 participants
- Registry
-
NCT04363697
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT04363697. Randomized; quadruple masking; primary purpose treatment. Start 2020-09-24 (actual); primary completion 2025-06-02 (actual). Results posted on 2026-06-16.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)
- Condition
- Acute Heart Failure
- Condition
- Heart Failure
- Intervention (Drug)
- Dapagliflozin
- Intervention (Drug)
- Placebo
- Lead sponsor
- The TIMI Study Group
- Collaborator
- AstraZeneca
- Collaborator
- Worldwide Clinical Trials
Record details
- Record id
cardio:ct-nct04363697- Content hash
65fa3b4cdc25427e0803ed63e1f1a1e64ccbf4a36d1785215fb1776fe5746474